ARGOS-CLIMBER is a phase 1/2 trial evaluating PSMA PET and MRI guided prostate SABR with a simultaneous boost to intraprostatic and nodal disease in men with unfavourable intermediate and high-risk prostate cancer. The updated results demonstrate acceptable safety and quality of life with high biochemical and imaging response rates.
No takes yet. Share an insight, caveat, or question.
Alayed et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: